Table 3. Prevalence ratios of CIN in those 50+ vs 30–49 years of age.
Crude prevalence ratio (95% CI) | Adjusted* prevalence ratio (95% CI) | |
Women with HIV | ||
Any hrHPV | ||
CIN2+ | 1.1 (0.80 to 1.6) | 1.1 (0.80 to 1.6) |
CIN3+ | 1.1 (0.70 to 1.6) | 1.1 (0.70 to 1.6) |
Women without HIV | ||
Any hrHPV | ||
CIN2+ | 0.78 (0.45 to 1.4) | 0.78 (0.45 to 1.4) |
CIN3+ | 0.81 (0.40 to 1.7) | 0.81 (0.40 to 1.7) |
Adjusted for history of cervical cancer screening.
CINcervical intraepithelial neoplasiaHPVhuman papillomavirus